Kymera Therapeutics shares are trading higher after the company announced it has completed enrollment in the global BROADEN2 Phase 2b trial of KT-621 nearly six months ahead of anticipated timelines.

Benzinga Newsdesk www.benzinga.com Positive 95.3%

Neg 0% Neu 0% Pos 95.3%

Comments

No comments yet. Be the first!